



Research Journal of **Microbiology**

ISSN 1816-4935



Academic
Journals Inc.

www.academicjournals.com



Research Article

First Report on the Antibiotic Resistance Profiles and Virulence Genes of *Staphylococcus pseudintermedius* Colonizing Dogs and Humans in Abakaliki, South-East Nigeria

¹I.B. Moses, ²C.O. Esimone, ¹I.R. Iroha, ¹E.N. Ugbo, ¹A.C. Nwuzo, ¹J.O. Orji, ¹E.A. Nwakaeze, ¹N.B. Agumah, ³A.A. Emioye, ¹E.G. Ukpai and ¹L.N. Ogene

¹Department of Applied Microbiology, Faculty of Science, Ebonyi State University, P.M.B. 053, Abakaliki, Ebonyi State, Nigeria

²Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka, Nigeria

³Department of Biology/Microbiology/Biotechnology, Alex Ekwueme Federal University, Ndufu-Alike, Ikwo, Ebonyi State, Nigeria

Abstract

Background and Objective: The increase in antibiotic-resistant *Staphylococcus pseudintermedius* among pets and the transfer of *S. pseudintermedius* from pets to humans threaten veterinary medicine and public health. The objective of this study was to determine the antibiotic resistance patterns and prevalence of virulence genes among *Staphylococcus pseudintermedius* isolates obtained from dogs and dog owners in Abakaliki, Nigeria. **Materials and Methods:** Swab samples from 112 shelter dogs and 97 dog owners were processed using standard microbiological procedures. Antibiotic susceptibility test was done by Kirby Bauer disc diffusion technique. Screening for virulence genes was done by Polymerase Chain Reaction (PCR). **Results:** Exactly 99 *S. pseudintermedius* isolates including 52 Methicillin Resistant *Staphylococcus pseudintermedius* (MRSP) strains were recovered from dogs and humans. *Sec*, *exi*, *siet* and *lukD* virulence genes were confirmed by PCR. Isolates were highly resistant (69.2-100%) to amoxicillin, cefepime and ceftazidime, but very susceptible (66.3-80.2%) to ofloxacin, doripenem, ertapenem and chloramphenicol. A total of 73 (73.7%), 2 (2%), 62 (62.6%) and 55 (55.6%) isolates harboured *sec*, *exi*, *siet* and *lukD* virulence genes, respectively. **Conclusion:** Isolates in this study harboured *sec*, *siet*, *exi* and *lukD* virulence genes and were also notably more resistant than those reported in literature. There was phenotypic homogeneity in the antibiotic resistance profiles of isolates from both humans and dogs in households that were sampled, thus depicting a possible zoonotic transmission event from dogs to their owners. Hence, monitoring of antimicrobial resistance, appropriate hygienic measures such as; hand washing after attending to dogs should be adopted so as to minimize the spread of resistance and virulence.

Key words: *Staphylococcus pseudintermedius*, zoonotic, Methicillin Resistant *Staphylococcus pseudintermedius* (MRSP), virulence genes, antibiotic resistance

Citation: I.B. Moses, C.O. Esimone, I.R. Iroha, E.N. Ugbo, A.C. Nwuzo, J.O. Orji, E.A. Nwakaeze, N.B. Agumah, A.A. Emioye, E.G. Ukpai and L.N. Ogene, 2020. First report on the antibiotic resistance profiles and virulence genes of *Staphylococcus pseudintermedius* colonizing dogs and humans in Abakaliki, South-East Nigeria. Res. J. Microbiol., 15: 22-34.

Corresponding Author: I.B. Moses, Department of Applied Microbiology, Faculty of Science, Ebonyi State University, P.M.B. 053, Abakaliki, Ebonyi State, Nigeria Tel: +2348134136233

Copyright: © 2020 I.B. Moses *et al.* This is an open access article distributed under the terms of the creative commons attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Competing Interest: The authors have declared that no competing interest exists.

Data Availability: All relevant data are within the paper and its supporting information files.

INTRODUCTION

Staphylococcus pseudintermedius is a normal flora of dogs but when their immune system is compromised, it becomes pathogenic and thus termed an opportunistic microorganism. It is a well-known cause of dermatologic infections such as; pyoderma, otitis externa and wound infections¹. It has been isolated from serious human infections particularly from people who are in close contact with pets such as; small animal veterinarians and pet owners^{2,3}. However, it has recently emerged as a dangerous opportunistic pathogen comparable to *S. aureus* in humans. Human infections with *S. pseudintermedius* are rare usually local and associated with bite wounds, but there are isolated reports of bacteremia, brain abscess, endocarditis, sinusitis, otitis, infected leg ulcers and pneumonia^{4,5}. Human infection, mainly acquired from dogs has however only recently been reported. The first case of human infection by *S. pseudintermedius* was described by Van Hoovels *et al.*⁶, causing endocarditis after the implantation of a Cardioverter Defibrillator Device (ICD). Since then human infections have been reported sporadically, including surgical site infections, rhinosinusitis and catheter associated bacteremia⁷. Most importantly, Methicillin Resistant *Staphylococcus pseudintermedius* (MRSP) has recently emerged as a significant public health problem in veterinary medicine and entails further consequences for humans. Moreover, the transmission of *S. pseudintermedius* and *S. aureus* between human and zoonotic hosts is evident and has resulted in severe infections in humans caused by MRSP^{8,9}. Consequently, the importance of this bacterium as a pathogen appears to be underestimated¹⁰. This underestimation has been shown in recent genomic data which clearly indicates that *S. pseudintermedius* is equipped with genes homologous to those encoding virulence factors and regulatory systems that are characteristic of *S. aureus*¹¹. Because, the therapeutic options are limited both for animals and humans, their increasing incidence is an alarming problem. *Staphylococcus pseudintermedius* harbour various virulence factors which are closely related to those harboured by *S. aureus*¹². It produces enzymes such as coagulase, DNase, protease, thermonuclease and toxins, including haemolysins and exfoliative toxins^{11,13}. *Staphylococcus pseudintermedius* also produces a leucotoxin known as Luk-I, which is very similar to Pantone-Valentine Leucocidin (PVL) from *S. aureus*^{14,15}. Knowledge of the pathogenesis of *S. pseudintermedius* remains yet limited. The resistance of *S. pseudintermedius* depends on geographical distribution as well as on other factors; thus,

it is important to obtain data from different countries to better understand the epidemiological spread of resistance¹⁶. This study, was therefore, designed to determine the antibiotic resistance patterns and to molecularly characterize *Staphylococcus pseudintermedius* isolates obtained from dogs and dog owners for various virulence genes in Abakaliki, South-east Nigeria.

MATERIALS AND METHODS

Study population: The study population were shelter dogs and humans (dog owners) living within Abakaliki Metropolis, Ebonyi state, South-East Nigeria. A total of 112 shelter dogs were sampled (one sample per dog) and 97 dog owners volunteered for the study between January, 2017 and February, 2018 from 69 different households. Also included in the study are 150 people who have no contacts with dogs. All samples were collected in triplicate from each dog and human.

Ethical consideration: Ethical clearance for the collection of bacterial isolates from dogs and humans (dog owners and non-dog owners) were obtained from the Ministry of Health, Ebonyi state (Reference number: SMOH/ERC/19/061). Informed consent of dog owners and other people (who had no contacts with dogs) were obtained prior to sample collection.

Sample collection: Sterile cotton swabs moistened in sterile normal saline were used to collect samples from dogs (nares, perineum and mouth) and humans (nasal swabs). These samples were delivered to the laboratory within few hours on the same day for bacteriological analysis.

Bacteriological analysis: Each swab sample was streaked onto already prepared mannitol salt agar (Oxoid, UK) and incubated at 35°C for 24 h. Colonies displaying typical *Staphylococcus pseudintermedius* characteristics (pink-yellow, yellow colonies) were picked and sub-cultured onto CHROM agar Staph aureus (CHROM agar, Paris, France) and incubated at 35°C for 24 h. After incubation, small blue colonies typical of *Staphylococcus pseudintermedius* were picked and further sub-cultured onto 5% sheep blood Columbia agar. Suspected *S. pseudintermedius* colonies on Columbia sheep blood agar (small, creamy grey to white, round colonies with a small margin and double zone of hemolysis) were then purified through successive streaking so as to obtain pure cultures. Purified colonies were then subjected to Gram-staining and catalase test. Presumptive

Staphylococcal colonies (Gram-positive cocci in bunches with positive catalase test) were further evaluated for coagulase production (tube coagulase using rabbit plasma), hyaluronidase test, acetoin production, beta-galactosidase production, pyrrolidonylarylamidase (PYR) test, DNase activity and some other biochemical tests such as maltose utilization and mannitol utilization^{17,18}. Identified *S. pseudintermedius* colonies were then preserved at -80°C in Trypticase Soy Broth (TSB) with 15% glycerol for further analysis, including molecular characterization.

Antibiotic susceptibility test and Methicillin Resistant *Staphylococcus pseudintermedius* (MRSP) determination:

This was used to determine the antibiotic susceptibility pattern of the *Staphylococcus pseudintermedius* isolates. Antibiotic susceptibility test was done using the Kirby Bauer disc diffusion method in accordance with Clinical Laboratory Standards Institute (CLSI) guidelines, M100-S24¹⁹. Mueller-Hinton agar (Oxoid, UK) was prepared according to the manufacturer's instructions. The medium was cooled to 45-50°C and poured into plates. Plates were allowed to set on a level surface to a depth of approximately 4 mm. When the agar has solidified, plates were allowed to dry before use. *Staphylococcus aureus* ATCC 29213 and *Enterococcus faecalis* ATCC 29212 were used as quality control strains. An 18-24 h old broth culture of the *Staphylococcus pseudintermedius* isolate was standardized by diluting to 0.5 McFarland's standard. A sterile swab stick was inserted into the standardized *Staphylococcus pseudintermedius* inoculum, drained to remove excess inoculum load and inoculated by spreading on the surface of prepared Mueller-Hinton agar plate. After this, the inoculated Mueller-Hinton agar plate was allowed to dry for a few minutes at room temperature with the lid closed. After the agar surface has dried for few minutes, antibiotic impregnated discs (Oxoid, UK) of known concentrations; amoxicillin-clavulanic acid (30 µg), cefepime (30 µg), ertapenem (10 µg), ofloxacin (5 µg), ciprofloxacin (5 µg), chloramphenicol (30 µg), levofloxacin (5 µg), doripenem (10 µg), ceftazidime (30 µg) and oxacillin+2% NaCl (1 µg) were carefully applied on the inoculated Mueller-Hinton agar plates using sterile forceps. The plates were then incubated at 37°C for 18-24 h. After incubation, the diameters of the zones of inhibition were measured with a ruler to the nearest millimeter and recorded. The results were recorded as resistant, intermediate and susceptible according to the guidelines of Clinical Laboratory Standards Institute (CLSI) guidelines, M100-S24¹⁹. Oxacillin antibiotic (with 2% NaCl) was used in MRSP determination. Isolates

were considered to be Methicillin Resistant *Staphylococcus pseudintermedius* (MRSP) when they exhibit resistance to oxacillin+2% NaCl (Inhibition zone diameter ≤ 17 mm).

Determination of Multiple Antibiotic Resistance Indices (MARI) of the isolates: The MARI of the bacterial isolates was calculated with the technique described by Christopher *et al.*²⁰ and Subramanian *et al.*²¹. This was calculated as the number of antibiotics to which the tested isolates were resistant to, divided by the total number of antibiotics to which the organisms were tested against.

Molecular characterization of *S. pseudintermedius* isolates

DNA extraction: DNA was extracted from overnight cultures of *S. pseudintermedius* grown at 37°C on blood agar plates isolates by boil prep technique using heat block matrix (VWR Digital Heat Block, Henry Troemner, LLC, USA). Sterile Eppendorf tubes were labelled in duplicates according to the isolates' codes and one set of the tubes was filled with 200 µL of sterile water each. The Eppendorf tubes filled with sterile water were used for isolate inoculation while the second set of Eppendorf tubes without sterile water was used for DNA storage. The first set of the tubes was each inoculated with a loopful of a 24 h old culture of the isolates. Next, each of the inoculated tube was vortexed for proper mixing. The vortexed tube was tapped occasionally to allow inoculum droplets drain down the tube. After this, the vortexed Eppendorf tube was fixed into the heat block boil prep machine and heated at 100°C for 10 min. After the boiling time of 10 min elapsed, the tubes were allowed to cool a bit for about 2-3 min before centrifuging them. The Eppendorf tube which now contains a mixture of the lysed bacterial cells and DNA was removed from the heat block matrix and centrifuged at 10,000 rpm for 2 min to isolate the bacterial cell's DNA. After centrifugation, the cell pellets settle at the bottom of the Eppendorf tube while the cell's DNA remain in the supernatant in the tube. The centrifuged Eppendorf tube was then removed from the centrifuge and the supernatant carefully aliquoted into the second set of pre-labelled empty Eppendorf tube. The second set of the Eppendorf tube which now contains the bacterial DNA was then put in small-sized boxes and kept in the refrigerator at -20°C for preservation and further use.

PCR conditions for the molecular detection of *siet*, *sec*, *exi* and *lukD* virulence genes: All isolates were screened for *siet*, *sec*, *exi* and *lukD* virulence genes by PCR using previously published primers²²⁻²⁴. Annealing temperatures and oligonucleotide primers used for the detection of the various

Table 1: Oligonucleotide primers used for the detection of virulence genes

Primer name	Sequence (5'-3')	Size (bp) and temperature (°C)	Target gene	Source
sec-F	GTCAGACCCAACACCAGACC	598 (66)	<i>sec</i>	Gharsa <i>et al.</i> ²²
sec-R	CGGCATCAAGTCATACCAGA			
siet-F	TGGCGGTACATATGAAAGTGA	601 (58)	<i>siet</i>	Gharsa <i>et al.</i> ²²
siet-R	TTTCAACTCTGCACGCAATC			
lukD-F	GGCCAAATGCAAGAGACTTT	513 (55)	<i>lukD</i>	Couto <i>et al.</i> ²³
lukD-R	CCAACCAGCATTCATGATTTT			
exi F	TGCAGTTGGGACTGTTTTTG	512 (61)	<i>exi</i>	Iyori <i>et al.</i> ²⁴
exi R	AACGTCCCCCTTTACCTACG			

resistance and virulence genes are all shown in Table 1. Amplification reaction were carried out in a 25 µL PCR mixture containing 17.55 µL of PCR water, 2.5 µL of 10x buffer, 1.25 µL of 50 mM MgCl₂, 0.5 µL of 2 mM dNTP, 1 µL primer 1 (Forward), 1 µL primer 2 (Reverse), 0.2 µL of *Taq* polymerase and 1 µL of the genomic DNA. The thermocycler (BIO-RAD Finnegan C1000 Touch™, USA) was programmed for optimum conditions. The PCR mixture was poured into microcentrifuge tubes and vortexed for proper mixing before loading them into the thermocycler. The PCR reaction for *siet* gene was performed as follows: an initial denaturation at 95°C for 5 min, 40 cycles of denaturation at 94°C for 30 sec, annealing temperature of 58°C for 30 sec, elongation at 72°C for 60 sec and final 10 min extension period at 72°C. The PCR reaction for *sec* gene was performed as follows: an initial denaturation at 95°C for 5 min, 40 cycles of denaturation at 94°C for 30 sec, annealing temperature of 66°C for 30 sec, elongation at 72°C for 60 sec and final 10 min extension period at 72°C. The PCR reaction for *exi* gene was performed as follows: an initial denaturation at 95°C for 5 min, 40 cycles of denaturation at 94°C for 30 sec, annealing temperature of 61°C for 30 sec, elongation at 72°C for 60 sec and final 10 min extension period at 72°C. The PCR reaction for *lukD* gene was performed as follows: an initial denaturation at 95°C for 5 min, 40 cycles of denaturation at 94°C for 30 sec, annealing temperature of 55°C for 30 sec, elongation at 72°C for 60 sec and final 10 min extension period at 72°C.

Agarose gel electrophoresis: Gel electrophoresis was used to detect amplified DNA products. DNA fragments were analyzed by electrophoresis in 1x TBE buffer (Fisher Scientific International Inc., USA) on a 1% Ultra Pure agarose gel (Invitrogen, UK) stained with ethidium bromide. A 1% (w/v) agarose gel was used to resolve the amplified Polymerase Chain Reaction (PCR) products of the *S. pseudintermedius* isolates. The 1% (w/v) agarose gel was prepared by combining 1 g agarose with 100 mL of 1X TBE ((Tris-borate-EDTA) buffer in a 250 mL conical flask and heated in a microwave for about 2 min until the agarose was completely dissolved. The agarose solution was allowed to cool to about 60°C. After cooling, 1 µL

of ethidium bromide (10 mg mL⁻¹) was added to the dissolved agarose solution with swirling to mix. The melted agarose was then poured into a gel electrophoresis mould and the casting combs were inserted. It was allowed to gel for 30 min. The casting comb was then carefully removed after the gel had completely solidified. The solidified agarose gel was then carefully placed in the gel electrophoresis tank. One times concentration (1X) TBE electrophoresis buffer was then added to the Gel electrophoresis tank until the buffer just covered the agarose gel. Exactly 3 µL of amplified PCR products was mixed with 2 µL of gel tracking dye (bromophenol blue) and loaded in the sample wells of the prepared agarose gel (the marker was loaded on lane 1 followed by the controls and later followed by the samples). The electrophoresis tank was then covered and the electrodes were connected to the power pack (BIO-RAD, BIO-RAD Laboratories, USA) in such a way that the negative terminal is at the end where the samples have been loaded. The agarose gel was then subjected to electrophoresis at 90 volts for 30 min. TrackIt™ 100 bp DNA ladder (Invitrogen, Thermo Fisher Scientific, USA) was used as the molecular weight marker. At the completion of electrophoresis, electrodes were then disconnected and the power pack was turned-off. After this, the gel was removed from the buffer and the band pattern images of the DNA fragments in the gel were viewed using the Molecular Imager® (Gel Doc™ XR, BIO-RAD Laboratories, inc., USA) documentation system.

Statistical analysis: Statistical analysis was performed using SPSS 16.0 version statistical software package. Comparison between categorical variables was calculated using the t-test, ANOVA and Tukey *post hoc* multiple comparison test. Results were considered statistically significant if the p-value is less than 0.05 (p<0.05).

RESULTS

Prevalence of *S. pseudintermedius* isolates in dogs and dog owners (humans): Out of the 45 perineum swab samples, 42 (93.3%) were positive for *S. pseudintermedius*

Table 2: Prevalence of *S. pseudintermedius* isolates in dogs based on sample site

Sample site	Total no. of dog sampled	Total no. of <i>S. pseudintermedius</i> isolates obtained	
		Number	Percentage
Perineum	45	42	93.3
Nares	35	25	71.4
Mouth	32	19	59.4
Total	112	86	76.8

p-value: 0.074

Table 3: Prevalence of Methicillin Resistant *Staphylococcus pseudintermedius* (MRSP) isolates among dogs and human (dog owners) isolates

Sample source	Total number of MRSP isolates
Dogs	46
Humans (dog owners)	6
Total	52 (52.5%)

p-value: 0.417

while 25 (71.4%) out of the 35 nares swab samples were positive for *S. pseudintermedius*. A total of 19 (59.4%) swab samples were positive for *S. pseudintermedius* out of the 32 mouth swab samples obtained from dogs. In total, 86 (76.8%) dogs were positive for *S. pseudintermedius* (Table 2). There was no statistically significant difference in the prevalence of *S. pseudintermedius* in the perineum, nares and mouth [$p = 0.074$ (at $p < 0.05$)]. A total of 97 nasal swab samples of dog owners that volunteered for this study were collected. Out of the 97 volunteers, 13 (13.4%) were positive for *S. pseudintermedius*. None of the nasal swab samples from the 150 volunteers who have no contacts with dogs was positive for *S. pseudintermedius*.

Prevalence of Methicillin Resistant *S. pseudintermedius* (MRSP) isolates among dog and humans (dog owners) isolates: A total of 52 (52.5%) out of all the 99 isolates from both shelter dogs and humans were Methicillin Resistant *Staphylococcus pseudintermedius* (MRSP) as they were resistant to oxacillin with 2% NaCl. Out of the 52 MRSP isolates, 46 were from dogs while six were from humans (dog owners) (Table 3). There was no statistically significant difference in the prevalence of Methicillin Resistant *Staphylococcus pseudintermedius* (MRSP) isolates between dogs and humans [$p = 0.417$ (at $p < 0.05$) (Table 3)].

Percentage occurrence of responses of the *S. pseudintermedius* isolates from dogs to antibiotics tested: Antibiotic susceptibility test results revealed that *S. pseudintermedius* isolates from dogs were highly resistant to ceftazidime and Amoxicillin-clavulanic acid with resistance frequencies of 95.3 and 94.2%, respectively (Table 4).

Resistance was also observed to cefepime (80.2%), levofloxacin (51.2%) and ciprofloxacin (50%) (Table 4). Isolates were susceptible to ofloxacin (80.2%), chloramphenicol (76.9%), doripenem (66.3%) and ertapenem (66.3%). There was a statistically significant difference in the mean percentage resistances of the *S. pseudintermedius* isolates from dogs [$p = 0.000$ (at $p < 0.05$)]. Results also showed that 46 (53.5%) of the dog isolates were methicillin-resistant strains as they were resistant to oxacillin with 2% NaCl (Table 4).

Percentage occurrence of responses of the *S. pseudintermedius* isolates from dog owners (humans) to antibiotics tested: Antibiotic susceptibility test results showed that *S. pseudintermedius* isolates from dog owners (humans) were highly resistant to ceftazidime, amoxicillin-clavulanic acid and cefepime with resistance frequencies of 100, 92.3 and 69.2%, respectively (Table 5). Isolates were susceptible to chloramphenicol (76.9%), doripenem (76.9%), ofloxacin (69.2%), levofloxacin (53.8%), ertapenem (53.8%) and ciprofloxacin (53.8%). There was a statistically significant difference in the mean percentage resistances of the *S. pseudintermedius* isolates from humans [$p = 0.000$ ($p < 0.05$) (Table 5)]. There was no statistically significant difference between the mean resistances of *S. pseudintermedius* from dogs when compared to those from humans ($p < 0.05$).

Prevalence of virulence genes among the *S. pseudintermedius* isolates from dogs and humans (dog owners): A total of 73 (73.7%), 2 (2%), 62 (62.6%) and 55 (55.6%) isolates harboured *sec*, *exi*, *siet* and *lukD* virulence genes respectively (Table 6, Fig. 1-4). Out of the 73 *sec* virulence genes, 62 (84.9%) were found in the dog isolates while 11 (15.1%) were found in the human (dog owners) isolates (Table 6, Fig. 1). One *exi* virulence gene was present in both a dog (D014) and human (D103) isolates (Table 6, Fig. 2). *Siet* virulence gene was present in 53 (85.5%) isolates while 9 (14.5%) were present in the human isolates (Table 6, Fig. 3).




Fig. 1: PCR amplification gel of *sec* virulence gene (598 bp) among the *S. pseudintermedius* isolates (lanes 1-29)
Lane M:100 bp marker, -: Negative control without DNA, +: *S. pseudintermedius* SP31 (positive control), Lanes 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 14, 20, 27 and 29 were positive for *sec* virulence gene




Fig. 2: PCR amplification gel of *exi* virulence gene (512 bp) among the *S. pseudintermedius* isolates (lanes 1-18)
Lane M:100 bp marker, -: Negative control without DNA, +: *S. pseudintermedius* MSSP19 (positive control), lane 11 was positive for *exi* virulence gene




Fig. 3: PCR amplification gel of *siet* virulence gene (601 bp) among the *S. pseudintermedius* isolates (lanes 1-18)
Lane M:100 bp marker, -: Negative control without DNA, +: *S. pseudintermedius* SPC20 (positive control), Lanes 2,4,5,6,8,9,10,11,14,15 and 17 were positive for *siet* virulence gene




Fig. 4: PCR amplification gel of *lukD* virulence gene (513 bp) among the *S. pseudintermedius* isolates (lanes 1-18)
Lane M:100 bp marker, -: Negative control without DNA, +: *S. pseudintermedius* SPC06 (positive control), Lanes 2,4,5,6,7,8,9,11,12,14,16,17 and 18 were positive for *lukD* virulence gene

Table 4: Percentage occurrence of responses of the *S. pseudintermedius* isolates obtained from dogs to different antibiotics

Antibiotics	Resistance		Susceptible	
	Number	Percentage	Number	Percentage
Amoxicillin-clavulanic acid (AMC)	81	94.2	5	5.8
Cefepime (FEP)	69	80.2	17	19.8
Ertapenem (ETP)	29	33.7	57	66.3
Ofloxacin (OFX)	17	19.8	69	80.2
Ciprofloxacin (CIP)	43	50.0	43	50.0
Chloramphenicol (C)	14	23.1	72	76.9
Levofloxacin (LEV)	44	51.2	42	48.8
Doripenem (DOR)	29	33.7	57	66.3
Ceftazidime (CAZ)	82	95.3	4	4.7
Oxacillin+2% NaCl (OXA ⁺)	46	53.5	40	46.5

p-value: 0.000

Table 5: Percentage occurrence of responses of the *S. pseudintermedius* isolates obtained from dog owners (humans) to different antibiotics

Antibiotics	Resistance (%)		Susceptible (%)	
	Number	Percentage	Number	Percentage
Amoxicillin-clavulanic acid (AMC)	12	92.3	1	7.7
Cefepime (FEP)	9	69.2	4	30.8
Ertapenem (ETP)	6	46.2	7	53.8
Ofloxacin (OFX)	4	30.8	9	69.2
Ciprofloxacin (CIP)	6	46.2	7	53.8
Chloramphenicol (C)	3	23.1	10	76.9
Levofloxacin (LEV)	6	46.2	7	53.8
Doripenem (DOR)	3	23.1	10	76.9
Ceftazidime (CAZ)	13	100.0	0	0.0
Oxacillin+2% NaCl (OXA ⁺)	6	46.2	7	53.8

p-value: 0.000

Table 6: Prevalence of virulence genes among *S. pseudintermedius* isolates from dogs and humans (dog owners)

Virulence gene	Isolate source	Total number of positive isolates	
		Number	Percentage
<i>Sec</i>	Dogs	62	84.9
	Humans	11	15.1
<i>Exi</i>	Dogs	1	50.0
	Humans	1	50.0
<i>Siet</i>	Dogs	53	85.5
	Humans	9	14.5
<i>LukD</i>	Dogs	48	87.3
	Humans	7	12.7

p-value: 0.628

Out of the 55 *lukD* virulence genes, 48 (87.3%) were found in the dog isolates while 7 (12.7%) were present in the human isolates (Table 6, Fig. 4). There was no statistically significant difference in the prevalence frequencies among the 4 virulence genes; *sec*, *exi*, *siet* and *lukD* [$p = 0.628$ (at $p < 0.05$)].

Antibiotypes and Multiple Antibiotic Resistance Index (MARI) values of *S. pseudintermedius* isolates: The Multiple Antibiotic Resistance Index (MARI) values of the

S. pseudintermedius isolates ranged from 0.2-0.9 (Table 7). Amoxicillin-clavulanic acid+ceftazidime resistance antibiotype (AMC^R CAZ^R) was the most prevalent antibiotype as it was present in virtually all the antibiotypes observed in Table 7 and 8. There was phenotypic homogeneity in the antibiotic resistance profiles of isolates obtained in each of the households that were sampled. Similarity in antibiotic resistance profiles were also observed between human and dog isolates in each household (Table 7 and 8).

Table 7: Antibiotic resistance profiles and identified genes in households where dog owners were positive for *S. pseudintermedius*

Household	Isolate source	Resistance profile	Virulence genes	MARI value
#3	Dog	MRSP FEP LEV CIP OFX DOR ETP	<i>Siet, lukD</i>	0.9
	Human	CHL AMC CAZ FEP OFX DOR ETP	<i>Sec, siet, lukD</i>	0.7
#4	Dog	CHL AMC CAZ	<i>Sec, siet, lukD</i>	0.3
	Human	CHL AMC CAZ	<i>Sec, siet, lukD</i>	0.3
#8	Dog	AMCCAZ FEP	<i>Sec, siet, lukD</i>	0.3
	Human	AMCCAZ FEP	<i>Sec, siet, exi, lukD</i>	0.3
#11	Dog	AMCCAZ FEP	<i>Sec, siet, exi, lukD</i>	0.3
	Human	AMCCAZ FEP	<i>Sec, siet, lukD</i>	0.3
#14	Dog 1	MRSP FEP LEV CIP OFX DOR ETP	<i>Siet</i>	0.9
	Dog 2	MRSP FEP LEV CIP OFX DOR ETP	<i>LukD</i>	0.9
	Human	MRSP FEP LEV CIP OFX ETP	<i>Sec</i>	0.8
#26	Dog	CHL MRSP FEP LEV CIP DOR ETP	-	0.9
	Human	CHL MRSP FEP LEV CIP DOR ETP	<i>Sec, siet</i>	0.9
#28	Dog	MRSP FEP LEV CIP OFX DOR ETP	-	0.9
	Human	MRSP FEP LEV CIP OFX ETP	<i>Sec</i>	0.8
#30	Dog 1	MRSP FEP LEV CIP DOR ETP	<i>Sec</i>	0.8
	Dog 2	MRSP FEP LEV CIP DOR ETP	<i>Sec, siet, lukD</i>	0.8
	Dog 3	MRSP FEP LEV CIP DOR ETP	<i>Sec</i>	0.8
	Human	MRSP FEP LEV CIP DOR ETP	<i>Sec</i>	0.8
#31	Dog	MRSP LEV CIP OFX DOR ETP	<i>Sec</i>	0.8
	Human	MRSP LEV CIP OFX DOR ETP	<i>Siet</i>	0.8
#44	Dog 1	AMC CAZ	<i>Sec, siet, lukD</i>	0.2
	Dog 2	AMC CAZ	<i>Sec, siet, lukD</i>	0.2
	Human	AMC CAZ	<i>Sec, siet, lukD</i>	0.2
#59	Dog	AMC CAZ	<i>Sec, siet, lukD</i>	0.2
	Human	AMC CAZ	<i>Sec, siet, lukD</i>	0.2
#63	Dog 1	MRSP FEP LEV CIP OFX DOR ETP	<i>Sec</i>	0.9
	Dog 2	MRSP FEP LEV CIP DOR ETP	<i>Siet</i>	0.8
	Human	MRSP FEP LEV CIP ETP	-	0.7
#69	Dog	AMC CAZ FEP DOR ETP	-	0.5
	Human	CAZ FEP	<i>Sec, siet, lukD</i>	0.2

CHL: Chloramphenicol, MRSP: OXA⁺ AMC CAZ, FEP: Cefepime, LEV: Levofloxacin, CIP: Ciprofloxacin, OFX: Ofloxacin, OXA⁺: Oxacillin+2% NaCl, AMC: Amoxicillin-clavulanic acid, CAZ: Ceftazidime, DOR: Doripenem, ETP: Ertapenem

Table 8: Antibiotic resistance profiles and identified genes in households with multiple dogs only

Household	Isolate source	Resistance profile	Virulence genes	MARI value
#1	Dog 1	MRSP FEP LEV CIP DOR ETP	<i>Sec</i>	0.8
	Dog 2	MRSP FEP LEV CIP DOR ETP	<i>Sec</i>	0.8
#7	Dog 1	MRSP LEV CIP DOR ETP	<i>Sec, lukD</i>	0.7
	Dog 2	MRSP LEV CIP DOR ETP	<i>Sec, lukD</i>	0.7
#10	Dog 1	MRSP FEP LEV CIP	<i>Siet</i>	0.6
	Dog 2	MRSP LEV CIP	-	0.5
#23	Dog 1	MRSP LEV CIP	<i>Siet, lukD</i>	0.5
	Dog 2	MRSP FEP LEV CIP DOR ETP	<i>Sec, siet, lukD</i>	0.8
	Dog 3	MRSP FEP LEV CIP DOR ETP	-	0.8
#24	Dog 1	MRSP FEP LEV CIP DOR ETP	-	0.8
	Dog 2	MRSP FEP LEV CIP DOR ETP	-	0.8
#32	Dog 1	MRSP LEV CIP	<i>Sec</i>	0.5
	Dog 2	MRSP FEP LEV CIP	<i>Sec</i>	0.6
#39	Dog 1	MRSP LEV CIP	-	0.5
	Dog 2	MRSP FEP LEV CIP DOR ETP	-	0.8
#43	Dog 1	MRSP LEV CIP OFX	<i>Sec, siet</i>	0.6
	Dog 2	MRSP FEP LEV CIP OFX	<i>Sec</i>	0.7
#46	Dog 1	MRSP FEP LEV CIP OFX ETP	<i>Sec</i>	0.8
	Dog 2	MRSP FEP LEV CIP DOR ETP	<i>Sec</i>	0.8
#49	Dog 1	MRSP FEP LEV CIP	<i>Sec</i>	0.6
	Dog 2	MRSP FEP LEV CIP OFX	<i>Sec, lukD</i>	0.7
	Dog 3	MRSP LEV CIP	<i>Siet</i>	0.5

CHL: Chloramphenicol, MRSP: OXA⁺ AMC CAZ, FEP: Cefepime, LEV: Levofloxacin, CIP: Ciprofloxacin, OFX: Ofloxacin, OXA⁺: Oxacillin+2% NaCl, AMC: Amoxicillin-clavulanic acid, CAZ: Ceftazidime, DOR: Doripenem, ETP: Ertapenem

DISCUSSION

Staphylococcus pseudintermedius is an important opportunistic pathogen of dogs. Increasing antimicrobial resistance by *S. pseudintermedius*, especially MRSP strains in dogs represents a major challenge for veterinarians in terms of antibiotic therapy³. This is the first study in Nigeria which reports *S. pseudintermedius* colonization in both dogs and dog owners. The *S. pseudintermedius* isolates from this study, including the MRSP strains were multi-drug resistant and more prevalent in dogs than among dog owners. Isolates were notably more resistant than those reported in literature and harboured virulence genes encoding various pathogenic factors. Interestingly, there was phenotypic homogeneity in the antibiotic resistance profiles of isolates from both dogs and dog owners in each household that was sampled, thus depicting a possible zoonotic transmission event from dogs to their owners. The carriage frequencies of *S. pseudintermedius* among shelter dogs and dog owners in this study were 76.8 and 13.4%, respectively. All the nasal swab samples from 150 volunteers who had no contact with dogs were negative for *S. pseudintermedius*. Among the three major dog sites that were sampled (perineum, nares and mouth) for *S. pseudintermedius*, the perineum was the most colonized site with a recovery frequency of 93.3%. This was closely followed by the nares and the mouth with recovery frequencies of 71.4 and 59.4%, respectively. The *S. pseudintermedius* isolates exhibited resistance (100-50%) to ceftazidime, amoxicillin-clavulanic acid, cefepime, levofloxacin and ciprofloxacin. Isolates also exhibited multi-drug resistant traits as they were resistant to at least three different classes of antibiotics. There was a statistically significant difference in the mean percentage resistances of the *S. pseudintermedius* isolates from dogs [$p = 0.000$ (at $p < 0.05$)]. However, isolates were highly susceptible (80.2-66.3%) to ofloxacin, chloramphenicol, doripenem and ertapenem. The Multiple Antibiotic Resistance Index (MARI) values of the *S. pseudintermedius* isolates in this study ranged from 0.2-0.9, thus further depicting multidrug resistance and the gradual phasing out of the tested antibiotics in treating infections caused by *S. pseudintermedius*. This study revealed that 46 (53.5%) of the *S. pseudintermedius* isolates from dogs and 6 (46.2%) of those from dog owners were methicillin-resistant strains. Amoxicillin-clavulanic acid+ceftazidime resistance antibiotype (AMC^R CAZ^R) was the most prevalent antibiotype as it was present in virtually all the antibiotypes observed. Interestingly, there was phenotypic homogeneity in the antibiotic resistance profiles of isolates obtained from dogs

and their owners in each of the households that were sampled, thus depicting a possible zoonotic transmission event between dogs and their owners. The *S. pseudintermedius* isolates in this study harboured *sec*, *exi*, *siet* and *lukD* virulence gene encoding pathogenic factors. *Sec* gene, mostly implicated in dog pyoderma cases was the most predominant virulence gene detected among the 99 isolates as 73 (73.7%) of the isolates were positive. This was closely followed by *siet* gene [62 (62.6%)] and *lukD* gene [55 (55.6%)], while *exi* gene [2 (2%)] was the least predominant. The 76.8% *S. pseudintermedius* carriage frequency among dogs in this study was higher than the 55% carriage frequency reported by Gharsa *et al.*²² in Tunisia, North Africa, but less than the 90% carriage frequency reported by Rubin and Chirino-Trejo²⁵ in Western Canada. Although few human cases have been described by Stegmann *et al.*⁵, Van Hoovels *et al.*⁶, Chuang *et al.*⁷ and Savini *et al.*⁸, the presumptive transmission of *S. pseudintermedius* from dogs to dog owners has also been reported as 3.9-13% of those humans have been found to harbor *S. pseudintermedius*^{3,26-28}. Even though the resistance frequencies of the *S. pseudintermedius* isolates in this study is higher than those reported in other studies, similar *S. pseudintermedius* resistance to beta-lactams, fluoroquinolones and chloramphenicol have been reported by Rubin *et al.*¹⁸, Gharsa *et al.*²² and Saab *et al.*²⁹. The prevalence frequency of MRSP among dogs in this study is far higher than the 0.8-7% prevalence frequency reported by Priyantha *et al.*³⁰, Ruscher *et al.*³¹ and Griffeth *et al.*³² in North America and Europe^{9,33,34}. This study is in total concord with other studies from Asia where 32-45% MRSP carriage frequency was reported in Thailand, Japan and Hong Kong^{26,35,36}. Gharsa *et al.*²², Ruzauskas *et al.*³⁷, Pitchenin *et al.*³⁸, Garbacz *et al.*³⁹, Matanovic *et al.*⁴⁰ and Ruscher *et al.*⁴¹ reported *luk* virulence gene in 29-95% of *S. pseudintermedius* isolates in their studies. In this study, the high prevalence frequency of *siet* gene (62.6%), responsible for the production of an exfoliative toxin, mostly associated with skin infections in dogs in agreement with the 69 and 91% prevalence frequency reported by Ruzauskas *et al.*³⁷ and Pitchenin *et al.*³⁸ in Lithuania and Brazil, respectively. This study also agrees with other studies on canine *S. pseudintermedius* in Korea⁴², Poland³⁹ and Tunisia²². Interestingly, most of the isolates that harboured *lukD* gene also harboured *siet* gene. This was also reported by Ruzauskas *et al.*³⁷ and Borjesson *et al.*⁴³. Contrastingly, Borjesson *et al.*⁴³ reported 8% prevalence for *sec* virulence gene. This frequency value (8%) for *sec* virulence gene reported by Borjesson *et al.*⁴³ does not completely agree with the 73.7% prevalence in this study. The

occurrence of virulence genes encoding toxins among the *S. pseudintermedius* isolates in this study is ubiquitous with the exception of *exi* gene which was present in just 2% of the isolates. The high frequency of isolates harbouring a significant number of these virulence genes suggests that these genes may play an important role in infection caused by *S. pseudintermedius*. The epidemiological situation of *S. pseudintermedius* infections is further exacerbated as the gene driving the drug resistance is highly mobile and can be transferred between different staphylococcal species colonizing humans and zoonotic hosts¹⁰. It is therefore pertinent to further investigate the diversity and dissemination of *S. pseudintermedius* infections in both dogs and humans so as to better understand their pathogenesis, risk factors and transmission characteristics which will greatly help in developing strong mitigation and control strategies and for future epidemiological studies.

CONCLUSION

Staphylococcus pseudintermedius isolates in this study were notably more resistant than those reported in literature. This study revealed that amoxicillin-clavulanic acid, ceftazidime and cefepime are no longer effective in treating bacterial infections caused by *S. pseudintermedius* isolates in Ebonyi state as a large number of the isolates obtained in this study were resistant to these antibiotics. This study also showed that ofloxacin, chloramphenicol, doripenem and ertapenem are still highly active against *S. pseudintermedius* and MRSP isolates from both dogs and humans in Ebonyi state. The *S. pseudintermedius* isolates from dogs and dog owners in this study harboured *sec*, *siet*, *exi* and *lukD* virulence genes. High prevalence of isolates positive for a significant number of these toxin genes suggests that these genes may play an important role in infection caused by *S. pseudintermedius*. The strange phenotypic homogeneity in the antibiotic resistance profiles observed among human and dog isolates depicts a likely zoonotic transfer between the dogs and their owners. The ability of *S. pseudintermedius* to cause human infections highlights its lack of host specificity and the importance of considering inter-species transmission.

SIGNIFICANCE STATEMENT

This is the first study in Nigeria which reports the antibiogram and prevalence of *S. pseudintermedius*, including the methicillin-resistant strains among dogs and dog owners. This study is also the first to report the prevalence of various virulence genes; *sec*, *siet*, *exi* and *lukD* genes encoding different pathogenic factors among

S. pseudintermedius isolates obtained from dogs and dog owners. The high prevalence of *sec*, *siet* and *lukD* virulence genes in *S. pseudintermedius* isolates obtained from dogs and humans in this study indicates that these toxins may play an important role in the pathogenesis of infection and could be very important in active infection. High prevalence of isolates positive for a significant number of toxin genes suggests that these toxins may play an important role in infection caused by *S. pseudintermedius*. Knowledge about the toxigenic profile of *S. pseudintermedius* strains will greatly help in understanding the pathogenesis of infection caused by this microbe.

ACKNOWLEDGMENT

We appreciate Assistant Professor Joseph E. Rubin and Michelle Slade, Professor Janet Hill, Linda Nimeth, Lana Abrey and other staff in the Department of Veterinary Microbiology, Western College of Veterinary Medicine (WCVN), University of Saskatchewan, Canada for their amazing support in the molecular characterization (PCR) of our isolates in Canada.

REFERENCES

1. Petersen, A.D., R.D. Walker, M.M. Bowman, H.C. Schot and E.J. Rosser Jr., 2002. Frequency of isolation and antimicrobial susceptibility patterns of *Staphylococcus intermedius* and *Pseudomonas aeruginosa* isolates from canine skin and ear samples over a 6-year period (1992-1997). J. Am. Anim. Hosp. Assoc., 38: 407-413.
2. Guardabassi, L., M.E. Loeber and A. Jacobson, 2004. Transmission of multiple antimicrobial-resistant *Staphylococcus intermedius* between dogs affected by deep pyoderma and their owners. Vet. Microbiol., 98: 23-27.
3. Paul, N.C., A. Moodley, G. Ghibaudo and L. Guardabassi, 2011. Carriage of methicillin-resistant *Staphylococcus pseudintermedius* in small animal veterinarians: Indirect evidence of zoonotic transmission. Zoonoses Public Health, 58: 533-539.
4. Weese, J.S. and E. van Duin, 2010. Methicillin-resistant *Staphylococcus aureus* and *Staphylococcus pseudintermedius* in veterinary medicine. Vet. Microbiol., 140: 418-429.
5. Stegmann, R., A. Burnens, C.A. Maranta and V. Perreten, 2010. Human infection associated with methicillin-resistant *Staphylococcus pseudintermedius* ST71. J. Antimicrob. Chemother., 65: 2047-2048.
6. Van Hoovels, L., A. Vankeerberghen, A. Boel, K. van Vaerenbergh and H. de Beenhouwer, 2006. First case of *Staphylococcus pseudintermedius* infection in a human. J. Clin. Microbiol., 44: 4609-4612.

7. Chuang, C.Y., Y.L. Yang, P.R. Hsueh and P.I. Lee, 2010. Catheter-related bacteremia caused by *Staphylococcus pseudintermedius* refractory to antibiotic-lock therapy in a hemophilic child with dog exposure. J. Clin. Microbiol., 48: 1497-1498.
8. Savini, V., D. Barbarini, K. Polakowska, G. Gherardi and A. Bialecka *et al.*, 2013. Methicillin-resistant *Staphylococcus pseudintermedius* infection in a bone marrow transplant recipient. J. Clin. Microbiol., 51: 1636-1638.
9. Starlander, G., S. Borjesson, U. Gronlund-Andersson, C. Tellgren-Roth and A. Melhus, 2014. Cluster of infections caused by methicillin-resistant *Staphylococcus pseudintermedius* in humans in a tertiary hospital. J. Clin. Microbiol., 52: 3118-3120.
10. Van Duijkeren, E., B. Catry, C. Greko, M.A. Moreno and M.C. Pomba *et al.*, 2011. Review on methicillin-resistant *Staphylococcus pseudintermedius*. J. Antimicrob. Chemother., 66: 2705-2714.
11. Zakour, N.L.B., J. Bannoehr, A.H. van den Broek, K.L. Thoday and J.R. Fitzgerald, 2011. Complete genome sequence of the canine pathogen *Staphylococcus pseudintermedius*. J. Bacteriol., 193: 2363-2364.
12. Futagawa-Saito, K., M. Suzuki, M. Ohsawa, S. Ohshima, N. Sakurai, W. Ba-Thein and T. Fukuyasu, 2004. Identification and prevalence of an enterotoxin-related gene, *se-int*, in *Staphylococcus intermedius* isolates from dogs and pigeons. J. Applied Microbiol., 96: 1361-1366.
13. Fitzgerald, J.R., 2009. The *Staphylococcus intermedius* group of bacterial pathogens: Species re-classification, pathogenesis and the emergence of methicillin resistance. Vet. Dermatol., 20: 490-495.
14. Futagawa-Saito, K., S. Makino, F. Sunaga, Y. Kato, N. Sakurai-Komada, W. Ba-Thein and T. Fukuyasu, 2009. Identification of first exfoliative toxin in *Staphylococcus pseudintermedius*. FEMS Microbiol. Lett., 301: 176-180.
15. Futagawa-Saito, K., T. Sugiyama, S. Karube, N. Sakurai, W. Ba-Thein and T. Fukuyasu, 2004. Prevalence and characterization of leukotoxin-producing *Staphylococcus intermedius* in isolates from dogs and pigeons. J. Clin. Microbiol., 42: 5324-5326.
16. Geoghegan, J.A., E.J. Smith, P. Speziale and T.J. Foster, 2009. *Staphylococcus pseudintermedius* expresses surface proteins that closely resemble those from *Staphylococcus aureus*. Vet. Microbiol., 138: 345-352.
17. Cheesbrough, M., 2006. District Laboratory Practice in Tropical Countries. 2nd Edn., Cambridge University Press, UK., ISBN-13: 9781139449298, pp: 63-68.
18. Rubin, J.E., K.R. Ball and M. Chirino-Trejo, 2011. Antimicrobial susceptibility of *Staphylococcus aureus* and *Staphylococcus pseudintermedius* isolated from various animals. Can. Vet. J., 52: 153-157.
19. CLSI, 2014. Performance standards for antimicrobial susceptibility testing: Twenty-fourth informational supplement. Document No. M100-S24, Clinical and Laboratory Standards Institute, Wayne, PA., USA., January 2014.
20. Christopher, A.F., S. Hora and Z. Ali, 2013. Investigation of plasmid profile, antibiotic susceptibility pattern multiple antibiotic resistance index calculation of *Escherichia coli* isolates obtained from different human clinical specimens at tertiary care hospital in Bareilly-India. Ann. Trop. Med. Public Health, 6: 285-289.
21. Subramanian, P., N. Shanmugam, U. Sivaraman, S. Kumar and S. Selvaraj, 2012. Antibiotic resistance pattern of biofilm-forming uropathogens isolated from catheterised patients in Pondicherry, India. Australas. Med. J., 5: 344-348.
22. Gharsa, H., K.B. Slama, E. Gomez-Sanz, C. Lozano and N. Klibi *et al.*, 2013. Antimicrobial resistance, virulence genes and genetic lineages of *Staphylococcus pseudintermedius* in healthy dogs in Tunisia. Microb. Ecol., 66: 363-368.
23. Couto, N., A. Belas, M. Oliveira, P. Almeida, C. Clemente and C. Pomba, 2016. Comparative RNA-seq-based transcriptome analysis of the virulence characteristics of methicillin-resistant and -susceptible *Staphylococcus pseudintermedius* strains isolated from small animals. Antimicrob. Agents Chemother., 60: 962-967.
24. Iyori, K., K. Futagawa-Saito, J. Hisatsune, M. Yamamoto and M. Sekiguchi *et al.*, 2011. *Staphylococcus pseudintermedius* exfoliative toxin EXI selectively digests canine desmoglein 1 and causes subcorneal clefts in canine epidermis. Vet. Dermatol., 22: 319-326.
25. Rubin, J.E. and M. Chirino-Trejo, 2011. Prevalence, sites of colonization and antimicrobial resistance among *Staphylococcus pseudintermedius* isolated from healthy dogs in Saskatoon, Canada. J. Vet. Diagn. Invest., 23: 351-354.
26. Chanchaithong, P., V. Perreten, S. Schwendener, C. Tribuddharat, A. Chongthaleong, W. Niyomtham and N. Prapasarakul, 2014. Strain typing and antimicrobial susceptibility of methicillin-resistant coagulase-positive staphylococcal species in dogs and people associated with dogs in Thailand. J. Applied Microbiol., 117: 572-586.
27. Walther, B., J. Hermes, C. Cuny, L.H. Wieler and S. Vincze *et al.*, 2012. Sharing more than friendship-nasal colonization with Coagulase-Positive Staphylococci (CPS) and co-habitation aspects of dogs and their owners. PLoS ONE, Vol. 7. 10.1371/journal.pone.0035197.
28. Gomez-Sanz, E., C. Torres, S. Ceballos, C. Lozano and M. Zarazaga, 2013. Clonal dynamics of nasal *Staphylococcus aureus* and *Staphylococcus pseudintermedius* in dog-owning household members. Detection of MSSA ST³⁹⁸. PLoS ONE, Vol. 8. 10.1371/journal.pone.0069337.

29. Saab, M.E., J.S. Weese and J.T. McClure, 2017. Direct repeat unit (*dru*) typing and antimicrobial resistance of methicillin-resistant *Staphylococcus pseudintermedius* isolated from dogs in Atlantic Canada. Can. J. Vet. Res., 81: 192-198.
30. Priyantha, R., M.C. Gaunt and J.E. Rubin, 2016. Antimicrobial susceptibility of *Staphylococcus pseudintermedius* colonizing healthy dogs in Saskatoon, Canada. Can. Vet. J., 57: 65-69.
31. Ruscher, C., A. Lubke-Becker, C.G. Wleklinski, A. Soba, L.H. Wieler and B. Walther, 2009. Prevalence of methicillin-resistant *Staphylococcus pseudintermedius* isolated from clinical samples of companion animals and equidae. Vet. Microbiol., 136: 197-201.
32. Griffeth, G.C., D.O. Morris, J.L. Abraham, F.S. Shofer and S.C. Rankin, 2008. Screening for skin carriage of methicillin-resistant coagulase-positive staphylococci and *Staphylococcus schleiferi* in dogs with healthy and inflamed skin. Vet. Dermatol., 19: 142-149.
33. Kawakami, T., S. Shibata, N. Murayama, M. Nagata, K. Nishifuji, T. Iwasaki and T. Fukata, 2010. Antimicrobial susceptibility and methicillin resistance in *Staphylococcus pseudintermedius* and *Staphylococcus schleiferi* subsp. *coagulans* isolated from dogs with pyoderma in Japan. J. Vet. Med. Sci., 72: 1615-1619.
34. Gingrich, E.N., T. Kurt, D.R. Hyatt, M.R. Lappin and R. Ruch-Gallie, 2011. Prevalence of methicillin-resistant staphylococci in Northern Colorado shelter animals. J. Vet. Diagn. Invest., 23: 947-950.
35. Sasaki, T., K. Kikuchi, Y. Tanaka, N. Takahashi, S. Kamata and K. Hiramatsu, 2007. Methicillin-resistant *Staphylococcus pseudintermedius* in a veterinary teaching hospital. J. Clin. Microbiol., 45: 1118-1125.
36. Epstein, C.R., W.C. Yam, J.S.M. Peiris and R.J. Epstein, 2009. Methicillin-resistant commensal staphylococci in healthy dogs as a potential zoonotic reservoir for community-acquired antibiotic resistance. Infect. Genet. Evol., 9: 283-285.
37. Ruzauskas, M., N. Couto, A. Pavilonis, I. Klimiene and R. Siugzdiniene *et al.*, 2016. Characterization of *Staphylococcus pseudintermedius* isolated from diseased dogs in Lithuania. Polish J. Vet. Sci., 19: 7-14.
38. Pitchenin, L.C., L.N.S. Brandao, J.M.A. Rosa, F.C. Kagueyama and A. da Silva Alves *et al.*, 2017. Occurrence of toxin genes in *Staphylococcus pseudintermedius* from diseased dogs and other domestic and wild species. J. Infect. Dev. Ctries., 11: 957-961.
39. Garbacz, K., S. Zarnowska, L. Piechowicz and K. Haras, 2013. Pathogenicity potential of *Staphylococcus pseudintermedius* strains isolated from canine carriers and from dogs with infection signs. Virulence, 4: 255-259.
40. Matanovic, K., S. Mekic and B. Seol, 2012. Antimicrobial susceptibility of *Staphylococcus pseudintermedius* isolated from dogs and cats in Croatia during a six-month period. Vet. Arhiv, 82: 505-517.
41. Ruscher, C., A. Lubke-Becker, T. Semmler, C.G. Wleklinski and A. Paasch *et al.*, 2010. Widespread rapid emergence of a distinct methicillin- and Multidrug-Resistant *Staphylococcus pseudintermedius* (MRSP) genetic lineage in Europe. Vet. Microbiol., 144: 340-346.
42. Terauchi, R., H. Sato, T. Hasegawa, T. Yamaguchi, C. Aizawa and N. Maehara, 2003. Isolation of exfoliative toxin from *Staphylococcus intermedius* and its local toxicity in dogs. Vet. Microbiol., 94: 19-29.
43. Borjesson, S., E. Gomez-Sanz, K. Ekstrom, C. Torres and U. Gronlund, 2015. *Staphylococcus pseudintermedius* can be misdiagnosed as *Staphylococcus aureus* in humans with dog bite wounds. Eur. J. Clin. Microbiol. Infect. Dis., 34: 839-844.